Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.
We analyzed 21 children with leukemia receiving haploidentical hematopoietic stem cell transplantation (haplo-HSCT) from killer immunoglobulin (Ig)-like receptors (KIR) ligand-mismatched donors. We showed that, in most transplantation patients, variable proportions of donor-derived alloreactive natural killer (NK) cells displaying anti-leukemia activity were generated and maintained even late after transplantation. This was assessed through analysis of donor KIR genotype, as well as through phenotypic and functional analyses of NK cells, both at the polyclonal and clonal level. Donor-derived KIR2DL1(+) NK cells isolated from the recipient displayed the expected capability of selectively killing C1/C1 target cells, including patient leukemia blasts. Differently, KIR2DL2/3(+) NK cells displayed poor alloreactivity against leukemia cells carrying human leukocyte antigen (HLA) alleles belonging to C2 group. Unexpectedly, this was due to recognition of C2 by KIR2DL2/3, as revealed by receptor blocking experiments and by binding assays of soluble KIR to HLA-C transfectants. Remarkably, however, C2/C2 leukemia blasts were killed by KIR2DL2/3(+) (or by NKG2A(+)) NK cells that coexpressed KIR2DS1. This could be explained by the ability of KIR2DS1 to directly recognize C2 on leukemia cells. A role of the KIR2DS2 activating receptor in leukemia cell lysis could not be demonstrated. Altogether, these results may have important clinical implications for the selection of optimal donors for haplo-HSCT.
Pende
Daniela
D
Immunologia, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy. daniela.pende@istge.it
Marcenaro
Stefania
S
Falco
Michela
M
Martini
Stefania
S
Bernardo
Maria Ester
ME
Montagna
Daniela
D
Romeo
Elisa
E
Cognet
Céline
C
Martinetti
Miryam
M
Maccario
Rita
R
Mingari
Maria Cristina
MC
Vivier
Eric
E
Moretta
Lorenzo
L
Locatelli
Franco
F
Moretta
Alessandro
A
D000293:Adolescent; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D005260:Female; D020544:Graft vs Leukemia Effect / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006650:Histocompatibility Testing; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology / Q000502:physiology*; D007938:Leukemia / Q000276:immunology / Q000628:therapy*; D008297:Male; D018579:Patient Selection; D054340:Receptors, KIR / Q000378:metabolism* / Q000502:physiology*; D013379:Substrate Specificity; D014019:Tissue Donors; D014180:Transplantation / Q000502:physiology; D014184:Transplantation, Homologous; D055815:Young Adult
C433932:KIR2DS2 protein, human; D054340:Receptors, KIR